We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Leczenie biologiczne przewlekłego zapalenia zatok – aktualny stan wiedzy.
- Authors
Czerwaty, Katarzyna; Dżaman, Karolina; Miechowski, Wiktor; Godlewska, Izabella
- Abstract
Biological treatment is a modern method of therapy that has recently found its application in the treatment of type 2 chronic rhinosinusitis (CRS) associated with eosinophilic inflammation and the Th2-dependent inflammatory reaction (involving interleukins 4, 5 and 13). The aim of the article is to present the current state of knowledge regarding the use of biological treatment as a new therapeutic option for patients with treatment-resistant CRS with nasal polyps. Biologics are monoclonal antibodies that help suppress abnormal responses by the immune system. They are widely used in neoplastic, inflammatory and allergic diseases. Currently, biological drugs can also be used in patients with CRS and include monoclonal antibodies directed against interleukin 4 receptors (dupilumab), interleukin 5 (benralizumab) and directly blocking interleukin 5 itself (mepolizumab, reslizumab) or free immunoglobulin E (omalizumab). In 2019, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved dupilumab for the treatment of CRS with nasal polyps. In Poland, none of the biological drugs has been included in the refunded list in the CRS treatment, and the high costs of treatment limit the possibility of using this therapeutic option by the majority of patients.
- Subjects
POLAND; IMMUNOGLOBULIN E; INTERLEUKIN receptors; MONOCLONAL antibodies; DUPILUMAB; EUROPEAN Medicines Agency; UNITED States. Food &; Drug Administration; ALLERGIES; NASAL polyps
- Publication
Polish Otorhinolaryngological Review / Polski Przegląd Otorynolaryngologiczny (Index Copernicus), 2022, Vol 11, Issue 2, p22
- ISSN
2084-5308
- Publication type
Article
- DOI
10.5604/01.3001.0015.8538